David M. Spencer, Ph.D.
Department of Pathology and Immunology
- Ph.D., Massachusetts Institute of Technology
- Postdoctoral, Stanford University
- Prostate cancer progression
- Immuno-gene therapy
- Development and application of conditional signaling molecules, especially chemically induced dimerization (CID)
- Development of enhanced dendritic cell-based vaccines for cancer
- Lapteva N, Seethammagari MR, Hanks BA, Jiang J, Levitt JM, Slawin KM, Spencer DM. Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Cancer Res. 2007. 67(21):10528-37.
- Park D, Lapteva N, Seethamagari M, Slawin KM, Spencer DM. An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat Biotechnol. 2006. 24:1581-90.
- Seethammagari M, Xie X., Greenberg NM, Spencer DM. EZC2-prostate offer both high-sensitivity and specificity for non-invasive imaging of prostate cancer progression and androgen receptor action. Cancer Res. 2006. 66:6199-209.
- Hanks BA, Jiang J, Singh RA, Song W, Barry M, Huls MH, Slawin KM, Spencer DM. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat Med. 2005. 11:130-7.
- Nikitina EY, Desai SA, Zhao X, Song W, Luo AZ, Gangula RD, Slawin KM, Spencer DM. Versatile prostate cancer treatment with inducible caspase and interleukin-12. Cancer Res. 2005. 65:4309-19.
- Freeman KW, Welm BE, Gangula RD, Rosen JM, Ittmann M, Greenberg NM, Spencer DM. Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Res. 2003. 63:8256-63.
- Li B, Desai SA, MacCorkle-Chosnek RA, Fan L, Spencer DM. A novel conditional Akt “survival switch” reversibly protects cells from apoptosis. Gene Therapy. 2002. 9:233-44.